Commonwealth Biotechnologies, a Chesterfield-based biotech firm that has made several international deals lately, received a delisting notice from NASDAQ for failure to meet certain filing rules. The stock is down $0.11, or 17 percent, $0.53 in morning trading. (NASDAQ: CBTE) According to the notice dated July 24, Commonwealth failed to maintain a minimum stockholder’s equity… Read more »